IP Library › Granted Patent US 12,465,619
Granted Patent B2
US 12,465,619 · App. 17/253,081 · Granted Nov 11, 2025

Use of polar lipids to treat or prevent gestational diabetes mellitus

Inventors: Sophie Yvette Fabienne Christine Gallier (Auckland, NZ); Angela Marie Rowan (Auckland, NZ); Philip Newton Baker (Auckland, NZ)
Assignee: FONTERRA CO-OPERATIVE GROUP LIMITED
A61K35/20A23C9/1232A23C9/142A23C9/1528A23L33/115A23L33/135A23L33/40A61K35/747
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,619
App. No.
17/253,081
Granted
Nov 11, 2025
Kind
B2
Abstract

Methods of treating or preventing gestational diabetes mellitus (GDM) and/or treating or preventing one or more GDM-associated risks or one or more sequelae of GDM by administering one or more polar lipids, in addition to uses, compositions, and medicaments comprising one or more polar lipids to treat or prevent gestational diabetes mellitus and/or treat or prevent one or more GDM-associated risks or one or more sequelae of GDM.

Claims (22)

1 . A method of reducing the risk of gestational diabetes mellitus (GDM) in a pregnant subject in need thereof comprising:

administering daily at least 0.2 g of polar lipids derived from non-human mammalian milk for a minimum period of from 14 weeks to 22 weeks gestation, wherein the polar lipids comprise one or more phospholipids and one or more gangliosides.

2 . The method of claim 1 , wherein the polar lipids are administered in a composition comprising at least 1.5% by weight polar lipids relative to total lipids.

3 . The method of claim 1 , wherein the polar lipids, phospholipids and gangliosides are derived from bovine milk.

4 . The method of claim 1 , wherein the method comprises administering to the subject at least 10 mg of the one or more gangliosides derived from non-human mammalian milk per day.

5 . The method of claim 1 , wherein the one or more polar lipids are administered in a composition comprising a physiologically acceptable diluent, adjuvant, carrier or excipient.

6 . The method of claim 1 , wherein the one or more polar lipids are administered in a composition comprising, or in the form of, a food.

7 . The method of claim 6 , wherein the food is selected from cultured milk, yoghurt, cheese, milk drink and milk powder.

8 . The method of claim 1 , wherein the one or more polar lipids are administered in:

a. a composition that is a maternal formula or a maternal supplement, or

b. a composition that is a supplement or nutritional composition, optionally a formula, a dietetic product, or food.

9 . The method of claim 1 , wherein the one or more gangliosides comprises GD3, GM3 or a combination thereof; or wherein the one or more phospholipids comprises one or more phosphatidylcholines, one or more phosphatidylinositols, one or more phosphatidylserines, one or more lysophospholipids, one or more phosphatidylethanolamines, one or more sphingomyelins, one or more dihydrosphingomyelins, one or more glycerolphospholipids, phosphatidylglycerol, or a combination of any two or more thereof.

10 . The method of claim 1 , wherein the subject:

a. has an increased risk of GDM,

b. has previously suffered GDM,

c. is over the age of 35 years,

d. has previously been pregnant, or

e. any combination of any two or more of a) to d).

11 . The method of claim 1 , wherein the subject has high blood pressure.

12 . The method of claim 1 , wherein the method comprises administration of milk fat globule membrane material comprising the one or more polar lipids.

13 . The method of claim 1 , wherein the method further comprises separate, simultaneous, or sequential administration of a probiotic, wherein the probiotic comprises Lactobacillus rhamnosus HN001.

14 . The method of claim 1 wherein administration is continued daily throughout gestation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: GALLIER, SOPHIE YVETTE FABIENNE CHRISTINE; ROWAN, ANGELA MARIE; BAKER, PHILIP NEWTON
To: FONTERRA CO-OPERATIVE GROUP LIMITED
Reel/Frame 055649/0478 →
Priority Claims (1)
NZ 743704 · Jun 22, 2018 · national
Continuity (1)
Related Publication 20210113623A1 · Apr 22, 2021
References Cited (52)
US 20030060509A1 · Elswyk · 2003 [cited by applicant]
US 20100068293A1 · Dalemans · 2010 [cited by examiner]
US 20100331281A1 · Moore et al. · 2010 [cited by applicant]
US 20110177044A1 · Thomas et al. · 2011 [cited by applicant]
US 20160199331A1 · Oosting et al. · 2016 [cited by applicant]
US 20170000182A1 · Huber-Haag et al. · 2017 [cited by applicant]
US 20170007629A1 · Kuang et al. · 2017 [cited by applicant]
CN 102894369A · 2013 [cited by applicant]
CN 104853619A · 2015 [cited by applicant]
CN 106604651A · 2017 [cited by applicant]
CN 107890115 · 2018 [cited by applicant]
EP 2219652 · 2012 [cited by applicant]
WO WO2003082921 · 2003 [cited by applicant]
WO WO2004039430 · 2004 [cited by applicant]
WO WO2004066744 · 2004 [cited by applicant]
WO WO2006041316 · 2006 [cited by applicant]
WO WO2007043900 · 2007 [cited by applicant]
WO WO2007098564 · 2007 [cited by applicant]
WO WO2007123424 · 2007 [cited by applicant]
WO WO2007123425 · 2007 [cited by applicant]
WO WO2008055296 · 2008 [cited by applicant]
WO WO2008073448 · 2008 [cited by applicant]
WO WO2009067182 · 2009 [cited by applicant]
WO WO2013191542 · 2013 [cited by applicant]
WO WO2014056025 · 2014 [cited by applicant]
WO WO2016020489 · 2016 [cited by applicant]
WO WO2016020495 · 2016 [cited by applicant]
WO WO2016050758A1 · 2016 [cited by applicant]
WO WO2016198528 · 2016 [cited by applicant]
WO WO2017165287 · 2017 [cited by applicant]
WO WO2017176199A1 · 2017 [cited by applicant]
Extended European Search Report issued in application No. 19823558.2 on Feb. 17, 2022. [cited by applicant]
Wickens et al., “Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial”, British Journal of Nutrition, 117… [cited by applicant]
Baker et al. Milk fat globule membrane as a source of gangliosides and phospholipids during pregnancy to support healthy pregnancy and birth outcomes, Journal of Pediatric Gastroenterology and Nutrition (Apr. 2018) vol.… [cited by applicant]
Huang et al. (2017) The CLIMB (Complex Lipids In Mothers and Babies) study: protocol for a multicentre, three-group, parallel randomised controlled trial to investigate the effect of supplementation of complex lipids in… [cited by applicant]
Albert et al (2021) Supplementation with milk enriched with complex lipids during pregnancy: A double-blind randomized controlled trial. PLoS One 16(2):e0244916. https://doi.org/10.1371/journal.pone.0244916. [cited by applicant]
Harper et al. (2021) Development of spatiotemporal land use regression models for PM2.5 and NO2 in Chongqing, China, and exposure assessment for the CLIMB study. Atmospheric Pollution Research 12(7):e101096. https://doi… [cited by applicant]
Zhang et al. (2020) Five serum fatty acids are associated with subclinical hypothyroidism in a Chinese pregnant population. Scientific Reports 10:e6743. https://doi.org/10.1038/s41598-020-63513-7. [cited by applicant]
Zhang et al. (2021) Complex patterns of circulating fatty acid levels in gestational diabetes mellitus subclasses across pregnancy. Clinical Nutrition 40(6):4140-4148. [cited by applicant]
Chen et al. (2021) Associations of early pregnancy BMI with adverse pregnancy outcomes and infant neurocognitive development. Scientific Reports 11:e3793. https://doi.org/10.1038/s41598-021-83430-7. [cited by applicant]
Ye et al. (2021) Neonatal Milk Fat Globule Membrane Supplementation During Breastfeeding Ameliorates the Deleterious Effects of Maternal High-Fat Diet on Metabolism and Modulates Gut Microbiota in Adult Mice Offspring i… [cited by applicant]
Kanno C & Dong-Hyun K (1990) A simple procedure for the preparation of bovine milk fat globule membrane and a comparison of its composition, enzymatic activity, and electrophoretic properties with these prepared by othe… [cited by applicant]
Kanno C, Shimizu M & Yamachi K (1975) Isolation and physiochemical properties of a soluble glycoprotein fraction of milk fat globule membrane. Agric. Biol. Chem., 39(9):1835-1842. [cited by applicant]
Pruthi T D, Narayanan K M & Bhaleerao VR (1970) The role of milk phospholipids in the autoxidation of butterfat—I. Indian Journal of Dairy Science, 23:248-251. [cited by applicant]
Rombaut R, Camp JV, Dewettinck K. (2005) Analysis of phospho- and sphingolipids in dairy products by a new HPLC method. J Dairy Sci. 88(2), 482-8. [cited by applicant]
Rombaut R, Dejonckheere V, Dewettinck K., (2006) Microfiltration of butter serum upon casein micelle destabilization. J Dairy Sci. 89(6), 1915-25. [cited by applicant]
Rombaut R., Van Camp J. & Dewettinck K., (2006) Phospho- and sphingolipid distribution during processing of milk, butter and whey. International Journal of Food Science & Technology, 41(4):435-443. [cited by applicant]
Astaire J C, Ward R, German J B & Jimenez-Flores R (2003) Concentration of polar MFGM lipids from buttermilk by microfiltration and supercritical fluid extraction. J Dairy Sci. 86(7), 2297-307. [cited by applicant]
Boehm G and Moro G. Structural and Functional Aspects of Prebiotics Used in Infant Nutrition (2008) J. Nutr. 138(9), 1818S-1828S. [cited by applicant]
Lapolla et al. (2011) New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: a retrospective study on pregnan… [cited by applicant]
Diagnostic criteria and classification of hyperglycemia first detected in pregnancy: a World Health Organization Guideline. (2014) Diabetes Res. Clin. Pract. 103(3), 341-63. [cited by applicant]
McSweeney, Paul L. H et al. Advanced Dairy Chemistry, vol. 2: Lipids, vol. 2. pp. 19-27, 2020. [cited by applicant]